ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 752

Prevalence and Predictors of Peripheral Vascular Disease in a Cohort of Systemic Lupus Erythematosus (SLE) Patients

Ida Dzifa Dey1, Kelvin Acquaye2, Alfred Yawson3, Kofi Agyabeng4, Ernest Yorke5, Vincent Boima6 and Charles Mate-Kole7, 1Department of Medicine, Rheumatology Unit, School of Medicine and Dentistry,University of Ghana, Accra, Ghana, 2Department of Psychology, School of Medicine and Dentistry, Accra, Ghana, 3Department of Community Health, School of Medicine and Dentistry, Accra, Ghana, 4Department of Community Health, School of Medicine and Dentistry,University of Ghana, Accra, Ghana, 5Medicine, School of Medicine and Dentistry,University of Ghana, Accra, Ghana, 6School of Medicine and Dentistry,University of Ghana, Accra, Ghana, 7Department of Psychology, School of Medicine and Dentistry, University of Ghana, Accra, Ghana

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: Cardiovascular disease, risk and systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, October 21, 2018

Title: Systemic Lupus Erythematosus – Clinical Poster I: Clinical Manifestations and Comorbidity

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose:

Low Ankle-brachial index (ABPI) < 0.9 demonstrating peripheral vascular disease (PVD), is a marker of subclinical cardiovascular disease and it is an inexpensive and easy method in which to assess peripheral vascular disease (PVD). Cardiovascular morbidity in systemic lupus erythematosus (SLE) is at least as frequent as in age- and sex-matched type-1 diabetes mellitus patients, making SLE a cardiovascular disease equivalent. Therefore, aggressive screening and management of cardiovascular risk factors should be performed to reduce this risk and improve long term mortality from vascular events.

Methods:

The present study evaluated prevalence and risk factors for peripheral vascular disease in patients with SLE in a sub-Saharan country, Ghana. Secondly, it examined the correlates with disease characteristics, activity indices and traditional risk factors of atherosclerosis.

A prospective cohort of 77 Ghanaian female patients with SLE had clinical, laboratory parameters, disease activity, damage indices, treatment and traditional risk factors for atherosclerosis evaluated between those with and without PVD measured using ankle brachial pressure index (ABPI).

Results:

The prevalence of PVD was 22.73% with a mean age of 30.94 (SD ± 8.22) years (range: 20 – 60 years). Women with normal ABPI were older than those with abnormal ABPI, but this was not statistically significant (31.5 verses 28.5 years, p = 0.192).

From the multiple logistic regression model, prednisolone dosage, waist to height ratio (WHR), low density lipoprotein(LDL) as well as educational level were the statistically significant factors associated with higher prevalence of PVD (p<0.05). A unit increase in WHR decreased the odds of developing PVD by 0.0013 (95% CI: 0.00 – 0.18). Increase in prednisolone dosage increases the patient’s odds of developing PVD by 0.88(95% CI: 0.79 – 0.99). Each one unit rise in patient’s LDL increased their odds of getting PVD by 0.52(95% CI : 0.27 – 0.98). Patients odds of being diagnosed with PVD increased by 0.85(95% CI: 0.76 – 0.96) for each year after diagnosis. Higher educational level was associated with lower odds of developing PVD. Patients with tertiary education had 99% (AOR: 0.01, 95% CI: 0.00 – 0.47) lower odds of developing PVD.

Conclusion:

There is an increase prevalence of PAD in this Ghanaian cohort of SLE patients compared to the general public but lower than other SLE cohorts, despite being younger than other SLE cohorts and female. Traditional cardiovascular factors as well as disease related factors like disease duration and prednisolone use are associated. Follow up studies would see the impact of this on disease outcome and organ damage, especially on their neurocognitive effect which has not been studied previously.


Disclosure: I. D. Dey, None; K. Acquaye, None; A. Yawson, None; K. Agyabeng, None; E. Yorke, None; V. Boima, None; C. Mate-Kole, None.

To cite this abstract in AMA style:

Dey ID, Acquaye K, Yawson A, Agyabeng K, Yorke E, Boima V, Mate-Kole C. Prevalence and Predictors of Peripheral Vascular Disease in a Cohort of Systemic Lupus Erythematosus (SLE) Patients [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/prevalence-and-predictors-of-peripheral-vascular-disease-in-a-cohort-of-systemic-lupus-erythematosus-sle-patients/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/prevalence-and-predictors-of-peripheral-vascular-disease-in-a-cohort-of-systemic-lupus-erythematosus-sle-patients/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology